900
Participants
Start Date
October 23, 2024
Primary Completion Date
September 16, 2027
Study Completion Date
September 16, 2027
ofatumumab
This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.
DMT category 1
This is an observational study. There is no treatment allocation. The decision to continue their current DMT will be based solely on clinical judgement.
RECRUITING
Novartis Investigative Site, Berlin
RECRUITING
Novartis Investigative Site, Berlin
RECRUITING
Novartis Investigative Site, Hamburg
RECRUITING
Novartis Investigative Site, Itzehoe
RECRUITING
Novartis Investigative Site, Düsseldorf
RECRUITING
Novartis Investigative Site, Meerbusch
RECRUITING
Novartis Investigative Site, Remscheid
RECRUITING
Novartis Investigative Site, Essen
RECRUITING
Novartis Investigative Site, Duisburg
RECRUITING
Novartis Investigative Site, Bergneustadt
RECRUITING
Novartis Investigative Site, Siegen
RECRUITING
Novartis Investigative Site, Sundern Hachen
RECRUITING
Novartis Investigative Site, Bad Homburg
RECRUITING
Novartis Investigative Site, Stuttgart
RECRUITING
Novartis Investigative Site, Bad Krozingen
RECRUITING
Novartis Investigative Site, München
RECRUITING
Novartis Investigative Site, München
RECRUITING
Novartis Investigative Site, Untermeiting
RECRUITING
Novartis Investigative Site, Regensburg
RECRUITING
Novartis Investigative Site, Bogen
RECRUITING
Novartis Investigative Site, Tirschenreuth
RECRUITING
Novartis Investigative Site, Bamberg
RECRUITING
Novartis Investigative Site, Berlin
RECRUITING
Novartis Investigative Site, Bielefeld
RECRUITING
Novartis Investigative Site, Leipzig
RECRUITING
Novartis Investigative Site, Salzatal OT Salzmuende
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY